Evaluation of the efficacy and safety of Spinal-Z on clinical symptom of the patients with cancer of the upper part of the gastrointestinal tract

Baqiyatallah University of Medical Sciences0 个研究点目标入组 61 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•Patient with age of 25-75 year-old; Patients with gastric adenocarcinoma or Esophageal squamous cell carcinoma with standard treatment during the study; No sign of metastasis in the patients.
•Exclusion criteria: Participate in the study with use of any other drugs; history of bone marrow or stem cells transplants; Comorbidities include active infection, respiratory failure, heart failure or left ventricular EF <50%, inflammatory disorders, including rheumatoid arthritis and gout false, thyroid disorders or a history of thyroid antibodies, hyperviscosity syndrome, osteoporosis, anemia, bone marrow disorders such as sickle cell form, thalassemia or myelodysplastic syndrome, immune deficiency and psychiatric diseases that decreases the patient's tolerance; Pregnancy or lactation; Serum creatinine more than 1.5 times the maximum amount of the normal range; AST and ALT more than 1.5 times the upper limit of normal; Alkaline phosphatase greater than 2.5 times the upper limit of the normal range; Bilirubin more than 1.5 mg/dl.

发起方

Baqiyatallah University of Medical Sciences